Abstracts tagged "animal models and therapeutic targeting"

Abstract Number: 1447 • 2016 ACR/ARHP Annual Meeting
Therapeutic Blockade of Interleukin-6 Trans-Signalling Restores Vascular Function in Murine Collagen Induced Arthritis
Ruth Davies¹, Jessica O Williams², Katie Sime², Ellyn Hughes², Lauren A. Jordan², Charlotte Rawlings², Derek Lang³, Stefan Rose-John⁴, Simon A. Jones⁵, Anwen S. Williams² and Ernest H. Choy^6,7, ¹CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ²Institute of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ³Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴Institute of Biochemistry, Christian Albrechts University, Kiel, Germany, ⁵Infection, Immunity and Biochemistry, School of Medicine, Cardiff University, Cardiff, Wales, ⁶Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ⁷CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Mortality is increased in rheumatoid arthritis (RA), mainly due to cardiovascular disease (CVD). While molecular mechanisms underlining this clinical observation are unknown, systemic elevations…
Abstract Number: 1682 • 2015 ACR/ARHP Annual Meeting
Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor
Wan-Uk Kim¹, Eun-Jin Han², Chong-Hyeon Yoon³, Ki-Jo Kim⁴, Seung-Ah Yoo⁵, Bong Ki Hong⁵ and Saseong Lee⁵, ¹Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Institute of Bone & Joint Disease, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴St. Mary's Hospital, Seoul, South Korea, ⁵Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: We reported that nuclear factor of activated T-cells 5 (NFAT5), originally identified as an osmo-protective transcription factor, has a critical role in the pathogenesis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].